Ping An Expands Broad Health Interests With New Fund For Global Tech
China’s huge Ping An insurance group is continuing to build its investments in healthcare through a major new Hong Kong-based fund that will seek overseas technologies alongside the company’s steadily expanding interests in innovative drugs.
You may also be interested in...
A record-breaking private financing for a Chinese biotech has seen bets placed on Suzhou-based Innovent Biologics, which has 10 monoclonal antibodies including four biosimilars in its pipeline.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.